Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) is crucial for managing coronary artery disease (CAD).
• Optimal DAPT strategies require balancing atherothrombotic event risk against bleeding complications.
• Numerous clinical trials have explored antiplatelet selection and treatment duration in stable CAD and acute coronary syndromes.

Purpose of the Study:

• To compare and contrast recent focused updates on prescribing DAPT in CAD from the American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC).
• To highlight key differences in DAPT recommendations between the two major guidelines.
• To provide commentary on the reasons behind these guideline discrepancies.

Main Methods:

• Comparative analysis of current ACC/AHA and ESC guidelines on DAPT in CAD.
• Review of clinical trial evidence informing guideline recommendations.
• Expert commentary on the aetiology of differing recommendations.

Main Results:

• Both guidelines address DAPT in CAD, but present some divergent recommendations.
• Key differences exist in specific aspects of antiplatelet selection and treatment duration.
• The article elucidates the potential reasons for these variations in guidance.

Conclusions:

• Understanding the nuances between ACC/AHA and ESC DAPT guidelines is essential for optimal patient care in CAD.
• Clinicians should be aware of guideline differences to tailor therapy effectively.
• Further clarification on the evidence base may be needed to reconcile guideline disparities.